12/21/22 9:05 AMOTC : GTHP clinical trialfda approvalGuided Therapeutics Signs Agreement to Begin Clinical Trial for US FDA ApprovalGuided Therapeutics, Inc. or the“ Company”, the maker of LuViva, a rapid and painless cervical cancer detection system based on the Company’ s patented biophotonic technology, announced today it had executed a Clinical Trial Agreement with a prestigious academic medical institution. “Negotiating and signing the Clinical Trial...RHEA-AIvery positive
11/09/22 10:28 AMOTC : GTHP clinical trialGuided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of the LuViva Advanced Cervical ScanGuided Therapeutics, Inc., the maker of the LuViva Advanced Cervical Scan, based on its patented biophotonic technology, announced today that the clinical trial for Chinese regulatory is back on track after experiencing delays due to Covid-19 lockdowns and is expected to be completed and filed with the Chinese National Medical...RHEA-AIneutral
09/07/22 9:05 AMOTC : GTHP Guided Therapeutics Closes $3.3 Million Bridge FinancingGuided Therapeutics, Inc. or the“ Company”, the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it had raised approximately $3.3 million through the sale of 6.6 million shares of the Company’ s common stock at 50 cents each. For each common share purchased, the investors...RHEA-AIvery positive
07/20/22 9:00 AMOTC : GTHP clinical trialfda approvalGuided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical ScanGuided Therapeutics, Inc., the maker of a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced that it has obtained Institutional Review Board approval to initiate its clinical trial aimed at obtaining FDA approval for the Company’ s flagship product, the LuViva...RHEA-AIvery positive
03/31/22 9:05 AMOTC : GTHP clinical trialGuided Therapeutics Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740Guided Therapeutics, Inc., the maker of the LuViva Advanced Cervical Scan, announced today that testing of 150 patients has been completed in the ongoing clinical trial for Chinese National Medical Products Administration approval. “We are pleased to hear that LuViva has performed well and as expected in the first clinical trials in...RHEA-AIneutral
11/17/21 9:05 AMOTC : GTHP clinical trialGuided Therapeutics Announces Start of Chinese Clinical Trial for Approval to Market and Sell LuViva in ChinaGuided Therapeutics, Inc., the maker of the LuViva Advanced Cervical Scan, based on its patented biophotonic technology, announced today that enrollment and testing of patients has begun at the Department of Obstetrics& Gynecology Hospital of Fudan University located in Shanghai. Upon such submission, $620,000 is due to Guided...RHEA-AIneutral
10/05/21 9:05 AMOTC : GTHP clinical trialGuided Therapeutics Ships LuViva Devices to China for Start of Clinical Trial; Receives Additional $100,000 PaymentGuided Therapeutics, Inc., the maker of the LuViva Advanced Cervical Scan, based on its patented biophotonic technology, announced today that its Chinese partner, Shandong Yaohua Medical Instrument Corporation, had received ethics board approval and placed LuViva devices at two of the three participating hospitals for clinical...RHEA-AIvery positive
08/19/21 9:05 AMOTC : GTHP clinical trialGuided Therapeutics Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from ChinaGuided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva® Advanced Cervical Scan, based on its patented biophotonic technology, announced today it had passed the regulatory compliance review at the Department of Obstetrics & Gynecology Hospital of Fudan University located in Shanghai.RHEA-AIvery positive
07/28/21 9:00 AMOTC : GTHP New European Published Study Shows LuViva Detects 20% More Precancerous and Cancerous Cervical Disease than HPV TestGuided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, based on its patented biophotonic technology, announced today that an independent study of 166 women in Hungary showed that LuViva detected 20% more cervical precancer and cancer than the HPV test.RHEA-AIneutral
07/20/21 9:00 AMOTC : GTHP Guided Therapeutics Receives News from Chinese State Food and Drug Administration that LuViva Meets Product Technical RequirementsGuided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva™ Advanced Cervical Scan, based on its patented biophotonic technology, announced today its Chinese co-manufacturing partner and distributor for China, Shandong Yaohua Medical Instrument Corporation (SMI), has received notice from theRHEA-AIvery positive